Last reviewed · How we verify
LBH581
LBH581 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
LBH581 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | LBH581 |
|---|---|
| Also known as | Panobinostat |
| Sponsor | Southern Europe New Drug Organization |
| Drug class | PI3K delta and PI3K gamma inhibitor |
| Target | PI3K delta and PI3K gamma |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, LBH581 reduces the activity of the PI3K/AKT signaling pathway, which is involved in the regulation of immune cell function. This leads to a decrease in the proliferation and survival of immune cells, resulting in immunosuppressive effects.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |